Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19

• Status: Not yet recruiting
• Trial end date: 2022-06-09
• Target enrollment: 0
• Participant gender: All

Summary

Clinical, control, double-blind, randomized experimentation with N-acetylcysteine and bromhexine for COVID-19.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidade Federal do Ceara
• Collaborators: Ceará Health Secretariat - SESA; Central Laboratory of Public Health of Ceara - LACEN-CE; Health Surveillance Secretariat - SVS; Leonardo da Vinci Hospital - HLV; Municipal Health Secretary - SMS-Fortaleza; Paulista School of Medicine-EPM, UNIFESP; São José Hospital for Infectious Diseases - HSJ
• Treatments: Acetylcysteine; Ascorbic Acid; Bromhexine; N-monoacetylcystine

Criteria

The inclusion criteria will be:

1. patients with clinical signs and symptoms of COVID-19; and

2. patients over 18 years and below 60 years of age.

The exclusion criteria will be:

1. participate in another clinical intervention study;

2. you have a disease or other medical condition that prevents you from using the medications for this intervention;

3. patient incapable of ingesting, retaining and absorbing the intervention medications; and (d) is mentally disabled.